Comparison of Glycated Haemoglobin with Glycated Albumin as Glycemic Marker in Patients with Iron Deficiency Anaemia: Real-World Evidence from Indian Setting

Strict glycaemic management is cornerstone of metabolic control. We prospectively compared Glycated Albumin (GA) with Glycated Hemoglobin (HbA1c) for the preciseness as marker for glycemic indicator in T2DM patients presenting with iron deficiency anaemia (n=45). Patients were treated with IV iron therapy (Iron Isomaltoside) without changing the metabolic treatment protocol. Table summarises the progressive change over baseline, two and four weeks in Hemoglobin (Hb), FPG, HbA1c and GA. 25 patients (56%) were females; mean age was 52.1 ± 10.74 years. Hb was negatively correlated with HbA1c (r = - 0.001; p = 0.99 NS) and positively corelated with GA (r = 0.29; p = 0.44 NS). Mean (±SD) percentage difference in the target and achieved values of HbA1c (6.5%) and GA (<18%) was 6 (±3.6) and -19 (±10), respectively. All the patients achieved glycemic targets when assessed with GA in contrast to none achieving HbA1c targets. The (GA/HbA1c) ratio did not ranged widely (range 0.75), mean 2.1 (±0.27, 95% CI 1.9 to 2.3). HbA1c values may be misleading, whereas GA, which is independent of anemia would be a precise monthly glycemic indicator than HbA1c to evaluate the glycemic control and fluctuations, in patients with anaemia to achieve strict and early glycemic control and further optimise the treatment. The results need corroboration with larger studies. Disclosure H. Thacker: None. P. Nitey: None. B.M. Makkar: Advisory Panel; Self; Abbott, AstraZeneca, Biocon, Boehringer Ingelheim Pharmaceuticals, Inc., Eris Lifesciences, Novartis AG, Novo Nordisk Inc., Sanofi, USV Private Limited. Speaker’s Bureau; Self; Janssen Pharmaceuticals, Inc. A. Maheshwari: None.